OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Quick
Links
Past Charts
Valuation Tracker By Industry Sector
Valuation Tracker By Sector
The Viridian Value Tracker is the most comprehensive valuation product in the industry.
-
- A broad set of 12 valuation measures assures applicability, regardless of whether the company has analyst coverage or revenues. The typically presented EV/ Projected Revenues and EV/ Projected EBITDA are available for less than 1/3 of the cannabis companies we track.
- Most valuation studies present only the average valuation measures, while the Tracker goes one step further and shows the distribution of values (the quartiles, median, and dispersion) for each measure. This gives users a more complete view of how companies in the cohort group are valued.
Week ended 09/08/2023
Our sector trackers include ratios applicable to value companies with no analyst coverage and the more typical EV/ Revenues and EV/ EBITDA measures. For each valuation measure, we present the values for the lowest 25% of companies, the median, and the highest 25%. This gives investors a better understanding of the spread of values than a simple average, often presented but frequently seriously flawed by outliers. Cannabis valuations have been up since the HHS rescheduling recommendation, but not all sectors have gained. Psychedelics are challenging to value because so many of them are pre-revenue. One measure that makes good sense, though, is market to book, which measured a median of 1.15x as of 9/8/23, down from 1.26x on 8/25/23. Psychedelic valuations have deteriorated relative to plant-touching companies.
Week ended 09/08/2023
Our sector trackers include ratios applicable to value companies with no analyst coverage and the more typical EV/ Revenues and EV/ EBITDA measures. For each valuation measure, we present the values for the lowest 25% of companies, the median, and the highest 25%. This gives investors a better understanding of the spread of values than a simple average, often presented but frequently seriously flawed by outliers. Cannabis valuations have been up since the HHS rescheduling recommendation, but not all sectors have gained. Psychedelics are challenging to value because so many of them are pre-revenue. One measure that makes good sense, though, is market to book, which measured a median of 1.15x as of 9/8/23, down from 1.26x on 8/25/23. Psychedelic valuations have deteriorated relative to plant-touching companies.
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
